Semarion secures $3.8m funding

We are pleased to announce our latest investment in Semarion, a University of Cambridge spinout. The funding supports the expansion of manufacturing and commercial capacity for the SemaCyte microcarrier platform.

Cambridge, UK, 31 March 2026: Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today announced it has raised $3.8 million USD (£2.9 million GBP). The fundraise was led by Parkwalk, and joined by The FSE Group, Cambridge Enterprise Ventures, Oxford Innovation Finance, Found Capital, Cambridge Capital Group, and Start Codon. The investment will facilitate commercial expansion and scale manufacturing of the Company’s SemaCyte® platform which enables adherent cell models to be handled as assay-ready, barcoded reagents for more flexible, data-rich, scalable drug discovery.

With a growing pipeline of opportunities and strong industry interest, Semarion is focused on broad-scale customer adoption, strengthening partnerships and preparing for its next phase of growth. The funding will be used to drive further commercialization of the SemaCyte platform, enabling the Company to increase manufacturing throughput and expand the field application support team.

Semarion’s technology has already been adopted by leading global pharmaceutical organizations, including top 10 pharma companies, across the US and Europe, with multiple pilot programs progressing towards broader commercial rollout. The Company has also established collaborations with global life science tools providers including Revvity, which has integrated compatibility for SemaCyte detection into its imaging and analysis platforms1, and SPT Labtech, combining the microcarrier technology with SPT Labtech’s liquid handling platform to advance automated cell-based assay workflows2.

John Pearson, Chief Investment Officer, Parkwalk, said: “Parkwalk is excited to be supporting the development of Semarion’s technology that has the potential to make a step change in cell-based research, accelerating a critical path in drug discovery. We are backing a team that has proven it can execute in delivering a product that works and can be adopted in customer workflows. This funding will allow Semarion to scale, reaching its full potential and creating value for investors and making a real-world impact.”

Jeroen Verheyen, CEO and Co-Founder at Semarion, added: “This funding marks an important step as we scale to meet growing demand from the industry. Scientists are under increasing pressure to generate more cell-based data, improve automation and drive operational efficiency. SemaCytes enable them to do this within existing workflows and infrastructure, and we are now focused on translating that momentum into broader adoption.”

References:

  1. Revvity expands SemaCyte multiplexing workflows across Harmony and Signals Image Artist
  2. SPT Labtech and Semarion Collaborate to Advance Automated Cell-Based Assay Workflows
  3. Semarion raises £2.14 million GBP ($2.89 million USD) seed funding

To find out more about Semarion, visit their website or our portfolio page here.

The products shown on this website will place your capital at risk and investors may not get back the full amount invested. Past performance may not be repeated and is not indicative of future results.

Parkwalk funds invest in smaller and unquoted companies which carry a higher risk than many other forms of investment. There is no guarantee that target returns will be achieved. There is no liquid market for shares in unquoted companies and there can be difficulties, in valuing and disposing of investments in such companies. Tax reliefs will depend on the investors’ individual circumstance and are subject to change.

Parkwalk does not provide investment or tax advice, and the information on this website should not be construed as such. Parkwalk recommends investors seek advice from a regulated financial adviser that specialises in EIS fund investments before making an investment decision. An investment into any of the funds managed by Parkwalk may only be made on the basis of the information set out in the Information Memorandum and Key Information Document.

The information on this website is directed at United Kingdom residents only. Please confirm you have read this warning and are happy to proceed.